Tuesday, June 06, 2023
Waters Corporation has announced the launch of an innovative targeted imaging mass spectrometer, built on the Xevo™ TQ Absolute tandem quadrupole mass spectrometer. This new instrument, incorporating the Waters™ DESI XS source, offers unprecedented sensitivity and speed, surpassing discovery-based imaging systems. It allows precise determination of the presence and quantity of small molecule drug products in specific target areas such as the brain, liver, or lungs of test subjects.
The Xevo TQ Absolute system has already proven successful in various applications, including highly sensitive PFAS testing at parts-per-quadrillion levels. By combining it with the DESI XS source, drug development scientists gain an efficient tool to assess the effects of drugs at the site of action, facilitating comprehensive studies with statistical power.
Dr. Jephte Akakpo, a Post-Doctoral Research Fellow at the University of Kansas Medical Center, shared his positive experience using the DESI XS source paired with the Xevo TQ Absolute system. He emphasized the robustness of the DESI XS source, improved signal-to-noise ratio, and the ability to test hypotheses more effectively, thereby elevating quantitative MS imaging to new heights.
The direct-from-sample DESI/tandem quadrupole mass spectrometry approach offers diverse applications such as elucidating drug distribution in tissue sections, monitoring relevant biochemical pathways in toxicological studies, and classifying tissue while determining tumor margins.
At the ASMS conference, Waters is also presenting its comprehensive PFAS analytical workflow, featuring the ultra-sensitive Xevo TQ Absolute mass spectrometer, specialized chemistries, and software. This workflow empowers laboratories worldwide to upgrade their capabilities and meet the latest regulatory requirements for measuring parts-per-quadrillion levels of PFAS in air, water, soil, and food.
Source: prnewswire.com
